SCHEMBL30410698

SCHEMBL30410698

COc1cccc(NC(=O)CN(C)c2nc(-c3cc(OCCO)ccn3)nc3sc(C)c(C)c23)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GAA P10253 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23991581 1.00 SMN1; SMN2 (0.56) SMN1; SMN2LMNANPSR1MAPTKDM4E
SCHEMBL23991599 0.91 LMNA (0.45) SMN1; SMN2LMNANPSR1MAPTPOLB
SCHEMBL30411163 0.91 LMNA (0.45) SMN1; SMN2LMNANPSR1MAPTPOLB
SCHEMBL30411145 0.89 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPSR1MAPTKDM4E
SCHEMBL23991589 0.89 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPSR1MAPTKDM4E
SCHEMBL23991450 0.88 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPSR1MAPTGAA
SCHEMBL30411887 0.88 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPSR1MAPTGAA
SCHEMBL23991294 0.86 SMN1; SMN2 (0.48) SMN1; SMN2LMNANPSR1MAPTALDH1A1
SCHEMBL30411468 0.86 SMN1; SMN2 (0.48) SMN1; SMN2LMNANPSR1MAPTALDH1A1
SCHEMBL23991802 0.84 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPSR1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559502-B2 Thieno pyrimidines as ferroportin inhibitors Global Blood Therapeutics, Inc (US) 2026-02-24 — — US disclosed
US-20230159553-A1 THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-05-25 — — US disclosed
EP-4143197-A1 THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS Global Blood Therapeutics, Inc. (US) 2023-03-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159553-A1 THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 SMN1; SMN2 2084/4885LMNA 2258/4885NPSR1 3239/4885
US-12559502-B2 Thieno pyrimidines as ferroportin inhibitors HAMP, TFRC, SLC40A1 SMN1; SMN2 1963/4885LMNA 1020/4885NPSR1 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback